Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22355010.
- Also identified by DOI 10.1158/1078-0432.CCR-12-0151 and PMC identifier 3336075.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Second-line therapies are needed for patients with advanced hepatocellular carcinoma who progress after sorafenib. Positive signals seen with brivanib in phase II studies, reported herein, have yet to be confirmed in phase III trials. Identification of the molecular mechanisms driving sorafenib resistance should guide drug development strategies in this setting.
Medical subject headings
- Alanine
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Triazines